Catalyst Capital Advisors LLC Makes New $1.23 Million Investment in Teva Pharmaceutical Industries Ltd. $TEVA

Catalyst Capital Advisors LLC purchased a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the first quarter, HoldingsChannel reports. The firm purchased 40,900 shares of the company’s stock, valued at approximately $1,232,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd bought a new position in Teva Pharmaceutical Industries in the 4th quarter valued at about $25,000. Allworth Financial LP raised its position in Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares in the last quarter. Grove Bank & Trust lifted its stake in Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after purchasing an additional 750 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after purchasing an additional 345 shares in the last quarter. Finally, Global Retirement Partners LLC increased its stake in shares of Teva Pharmaceutical Industries by 27.3% in the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after purchasing an additional 292 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Insider Activity

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the transaction, the executive vice president directly owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. The trade was a 34.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Amir Weiss sold 10,679 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total transaction of $384,444.00. Following the transaction, the chief accounting officer owned 20,016 shares in the company, valued at $720,576. The trade was a 34.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 465,931 shares of company stock worth $16,332,989. 0.54% of the stock is owned by insiders.

Teva Pharmaceutical Industries Stock Down 0.7%

Shares of TEVA opened at $32.00 on Friday. The stock’s 50-day moving average price is $33.76 and its two-hundred day moving average price is $32.69. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The company has a market capitalization of $36.79 billion, a PE ratio of 24.06, a PEG ratio of 3.40 and a beta of 0.86. Teva Pharmaceutical Industries Ltd. has a 12 month low of $14.99 and a 12 month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The business had revenue of $3.98 billion during the quarter. On average, analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.99 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on TEVA shares. Bank of America raised their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Truist Financial raised their price target on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Piper Sandler restated an “overweight” rating and issued a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.